702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study
Keyword(s):
Keyword(s):
Keyword(s):
2018 ◽
Vol 36
(15_suppl)
◽
pp. 4500-4500
◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS238-TPS238
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2014 ◽
Vol 32
(4_suppl)
◽
pp. 520-520
Keyword(s):